At2g44630 Antibody

Here’s a structured FAQ collection for researchers working with At2g44630 Antibody, incorporating methodological guidance and evidence-based insights:

Advanced Research Questions

How to resolve contradictory results between WB and qPCR data for At2g44630 expression?

• Step 1: Verify antibody specificity via siRNA knockdown followed by WB/qPCR correlation analysis.

• Step 2: Check for post-translational modifications affecting antibody-epitope binding using phosphatase/kinase inhibitors .

• Step 3: Quantify protein vs. mRNA half-lives using cycloheximide/actinomycin D treatments .

What strategies improve antibody performance in low-abundance tissue samples?

How to design a robust kinetics study for At2g44630-ligand interactions?

• Use BLI with anti-human Fc sensors:

  • Immobilize antibody on sensors (Fig. S1)

  • Measure association/dissociation rates with purified At2g44630 ($k_{on}$: 1–5 × 10⁴ M⁻¹s⁻¹; $k_{off}$: 1 × 10⁻³ s⁻¹)

  • Validate using SPR (surface plasmon resonance) for comparison .

Technical Notes

• Storage Stability: Maintain at -80°C in 50% glycerol/PBS; avoid >3 freeze-thaw cycles .

• Lot Variability: Always include a reference sample when comparing data across antibody batches.

• Ethical Compliance: This antibody is for research only (RUO); therapeutic applications require additional Fc engineering .